Navigation Links
TorreyPines Therapeutics to Host First Quarter 2008 Results Conference Call and Webcast
Date:5/12/2008

LA JOLLA, Calif., May 12 /PRNewswire-FirstCall/ -- TorreyPines Therapeutics, Inc. (Nasdaq: TPTX) today announced that the company will conduct a conference call and audio webcast on Tuesday, May 13, 2008 at 11:00 a.m., Eastern Time (ET), in conjunction with the release of its financial results for the first quarter ended March 31, 2008. TorreyPines anticipates releasing its financial results at 7:30 a.m. ET on Tuesday, May 13, 2008.

To participate in this conference call, dial 719-325-4817, confirmation code 2644321 shortly before 11:00 a.m. ET. A replay of the call will be available from 2:00 p.m. ET. The replay number is 719-457-0820, confirmation code 2644321. The audio webcast can be accessed at: http://www.torreypinestherapeutics.com.

About TorreyPines Therapeutics

TorreyPines Therapeutics, Inc. is a biopharmaceutical company committed to providing patients with better alternatives to existing therapies through the research, development and commercialization of small molecule compounds. The company's goal is to develop versatile product candidates each capable of treating a number of acute and chronic diseases and disorders such as migraine, chronic pain, muscle spasticity and rigidity, xerostomia and cognitive disorders. The company is currently developing four product candidates: two ionotropic glutamate receptor antagonists and two muscarinic receptor agonists. Further information is available at http://www.torreypinestherapeutics.com.

Company Contact: Media Contact:

Craig Johnson David Schull

TorreyPines Therapeutics, Inc. Russo Partners, LLC

858-623-5665, x118 212-845-4271

cjohnson@torreypinestherapeutics.com david.schull@russopartnersllc.com

Investor Contact:

Rhonda Chiger

Rx Communications

917-322-2569

chiger@rxir.com


'/>"/>
SOURCE TorreyPines Therapeutics, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Related biology technology :

1. TorreyPines Therapeutics Reports Fourth Quarter and Full Year 2007 Financial Results and Highlights
2. TorreyPines Therapeutics Initiates Phase II Study of Muscarinic Agonist NGX267 for Treatment of Xerostomia
3. TorreyPines Therapeutics to Present at Susquehanna Financial Groups Second Annual SIGnificant Options in Healthcare Conference
4. TorreyPines Therapeutics Reports Third Quarter 2007 Results
5. TorreyPines Therapeutics to Present at Acumen BioFin Rodman & Renshaw 9th Annual Healthcare Conference
6. TorreyPines Therapeutics to Present at ThinkEquitys ThinkClinic Conference
7. TorreyPines Therapeutics and Eisai Co., Ltd. Extend Genetics Discovery Collaboration for Alzheimers Disease
8. TorreyPines Therapeutics to Present at ThinkEquitys G5 Conference
9. TorreyPines Therapeutics to Present at the NewsMakers in the Biotech Industry Conference
10. Synvista Therapeutics Increases Commercial Focus by Appointing David C. Tantillo Senior Director of Marketing and Sales
11. President and CEO of Velcura Therapeutics Inc. Named the 2008 Grant Thornton Leader and Innovator of the Year
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/28/2017)... , ... April 28, 2017 , ... ... organization (CRO) has validated a 0.2 ng/mL lower limit (LLOQ) assay for nicotine ... 0.5 ng/mL LLOQ assay, the ultra-low trace nicotine assay meets additional needs of ...
(Date:4/27/2017)... ... April 27, 2017 , ... ... today announced their digital pathology technology has the potential to eliminate subjectivity in ... centers in The Netherlands as part of the 2017 ISBI CAMELYON Digital ...
(Date:4/27/2017)... ... April 27, 2017 , ... Arrowhead Publishers is pleased to ... coming to San Diego, CA on September 27-28, 2017. Leaders from the pharmaceutical, ... advances in the treatment of various types of pain. There are also extended ...
(Date:4/27/2017)... Orleans, La. (PRWEB) , ... ... ... Monitoring Technologies today announced a comprehensive rebrand and a name change to ... for the industrial and laboratory monitoring of polymer and biopharmaceutical manufacturing processes ...
Breaking Biology Technology:
(Date:4/11/2017)... , April 11, 2017 NXT-ID, Inc. ... technology company, announces the appointment of independent Directors Mr. ... to its Board of Directors, furthering the company,s corporate governance ... Gino ... we look forward to their guidance and benefiting from their ...
(Date:4/5/2017)... NEW YORK , April 5, 2017 ... security, is announcing that the server component of the ... is known for providing the end-to-end security architecture that ... customers. HYPR has already secured over 15 ... system makers including manufacturers of connected home product suites ...
(Date:4/3/2017)... , April 3, 2017  Data captured ... engineering platform, detected a statistically significant association ... prior to treatment and objective response of ... potential to predict whether cancer patients will ... treatment, as well as to improve both pre-infusion ...
Breaking Biology News(10 mins):